Acumen Pharmaceuticals (ABOS) Liabilities and Shareholders Equity (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $133.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 34.65% year-over-year to $133.6 million; the trailing twelve-month figure through Mar 2026 stood at $570.6 million (down 42.91% YoY), and the FY2025 full-year result was $122.8 million, down 48.6% from the prior year.
• Liabilities and Shareholders Equity improved to $133.6 million in Q1 2026, from $122.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $310.1 million in Q4 2023 to a low of $122.8 million in Q4 2025.
• A 5-year average of $215.5 million and a median of $204.5 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 190.2% in 2022 and tumbled 48.6% in 2025, its largest moves.
• Tracing ABOS's Liabilities and Shareholders Equity over 5 years: stood at $196.6 million in 2022, then surged by 57.75% to $310.1 million in 2023, then dropped by 22.94% to $239.0 million in 2024, then tumbled by 48.6% to $122.8 million in 2025, then increased by 8.79% to $133.6 million in 2026.
• Business Quant data shows ABOS's Liabilities and Shareholders Equity at $133.6 million in Q1 2026, $122.8 million in Q4 2025, and $142.2 million in Q3 2025.